Birdshot Chorioretinitis in Patients Aged 80 and Older

Louis Debillon; Jennifer E Thorne; Elodie Bousquet; Pierre Duraffour; Souhila Kecili; Dominique Monnet; Antoine P Brézin

doi:10.1080/09273948.2023.2215322

Birdshot Chorioretinitis in Patients Aged 80 and Older

Ocul Immunol Inflamm. 2023 May 19:1-6. doi: 10.1080/09273948.2023.2215322. Online ahead of print.

Authors

Louis Debillon¹, Jennifer E Thorne², Elodie Bousquet¹, Pierre Duraffour¹, Souhila Kecili¹, Dominique Monnet¹, Antoine P Brézin¹

Affiliations

¹ Université Paris Cité, Centre d'ophtalmologie de l'Assistance Publique - Hôpitaux de Paris, Paris, France.
² Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

PMID: 37204866
DOI: 10.1080/09273948.2023.2215322

Abstract

Purpose: To assess the manifestations of birdshot chorioretinitis (BSCR) in patients aged 80 and over.

Design: Among patients with BSCR followed in the CO-BIRD prospective cohort (ClinicalTrials.gov Identifier: NCT05153057), we analyzed the subgroup of patients aged 80 and over.

Methods: Patients were assessed in a standardized manner. Confluent atrophy was defined as hypoautofluorescent spots on fundus autofluorescence (FAF).

Results: We included 39 (8.8%) of the 442 enrolled CO-BIRD patients. The mean age was 83.8 ± 3.7 years. The mean logMAR BCVA was 0.52 ± 0.76, with 30 patients (76.9%) having 20/40 or better in at least one eye. Thirty-five (89.7%) patients were receiving no treatment. Confluent atrophy in the posterior pole, disrupted retrofoveal ellipsoid zone and choroidal neovascularization were associated with logMAR BCVA >0.3 (p < .0001).

Conclusion: In patients aged 80 and over we observed a striking heterogeneity of outcomes, but most retained a BCVA that allowed them to drive.

Keywords: Birdshot chorioretinitis; choroid; immunosuppressive therapy; long-term; posterior uveitis.

Associated data

ClinicalTrials.gov/NCT05153057